Johnson & Johnson Aktie
| 126,22EUR | 0,54EUR | 0,43% |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,93 |
| Vanguard Group, Inc. (Subfiler) | 8,42 |
| The Vanguard Group, Inc. | 8,08 |
| State Street Corp. | 5,74 |
| Vanguard US Total Market Shares Index ETF | 2,85 |
| Vanguard Total Stock Market Index Fund | 2,85 |
| BlackRock Institutional Trust Co. NA | 2,52 |
| BlackRock Fund Advisors | 2,33 |
| Vanguard 500 Index Fund | 2,07 |
| State Farm Investment Management Corp. | 1,44 |
| Geode Capital Management LLC | 1,40 |
| Northern Trust Corp. | 1,31 |
| SPDR S&P 500 ETF | 1,08 |
| Norges Bank (13F) | 1,01 |
| Massachusetts Financial Services Co. | 1,00 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 127 100 | 126 400 | 134 000 | 135 100 | 132 200 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,55 | 0,57 | 0,57 | 0,60 | 0,62 |
Bilanz (in Mio. EUR) - Aktiva
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 60 210 | 65 032 | 43 088 | 46 033 | 45 274 |
| Summe Anlagevermögen | 91 011 | 97 544 | 94 741 | 90 232 | 88 152 |
| Summe Aktiva | 133 411 | 141 208 | 157 303 | 152 954 | 157 728 |
Bilanz (in Mio. EUR) - Passiva
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 19 861 | 27 126 | 34 581 | 30 480 | 28 681 |
| Summe Fremdkapital | 62 261 | 70 790 | 97 143 | 93 202 | 98 257 |
| Summe Eigenkapital | 71 150 | 70 418 | 60 160 | 59 752 | 59 471 |
| Summe Passiva | 133 411 | 141 208 | 157 303 | 152 954 | 157 728 |
Adresse
| One Johnson & Johnson Plaza, 08933 New Brunswick | |
| Telefon | +1 (732) 524-0400 |
| Internet | http://www.jnj.com |
Management
|
A. Eugene Washington
Independent Director |
|
Alex Gorsky
Chairman & Chief Executive Officer |
|
Anne M. Mulcahy
Lead Independent Director |
|
Charles O. Prince
Independent Director |
|
Chris DelOrefice
Vice President-Investor Relations |
|
Ciro Römer
Company Group Chairman |
|
D. Scott Davis
Independent Director |
|
Euan Stuart Thomson
Global Head-Digital Technology |
|
Frederic H. Moll
Chief Development Officer |
|
Hubert Joly
Independent Director |
|
Ian Edward Lamert Davis
Independent Director |
|
James D. Swanson
Global Chief Information Officer & Executive VP |
|
Jennifer A. Doudna
Independent Director |
|
Jennifer Taubert
EVP & Worldwide Chairman-Pharmaceuticals |
|
Joaquin Duato
Vice Chairman-Executive Committee |
|
Joseph J. Wolk
Chief Financial Officer & Executive Vice President |
|
Kathleen M. Widmer
Chairman-Consumer North America |
|
Lisa Romanko
Senior Director-Investor Relations |
|
Marillyn A. Hewson
Independent Director |
|
Mark Alan Weinberger
Independent Director |
|
Mark B. McClellan
Independent Director |
|
Mary C. Beckerle
Independent Director |
|
Mathai Mammen
Head-Science & Development |
|
Matthew Orlando
Secretary |
|
Matthew Stuckley
Senior Finance Director |
|
Michael H. Ullmann
Executive Vice President & General Counsel |
|
Paulus Stoffels
Chief Scientific Officer |
|
Peter M. Fasolo
Chief Human Resources Officer & Executive VP |
|
Peter Shen
Global Head-Research & Development |
|
Robert J. Decker
Chief Accounting Officer |
|
Ronald A. Kapusta
Chief Accounting Officer & Controller |
|
Ronald A. Williams
Independent Director |
|
Sarah L. Colamarino
Vice President-Corporate Equity |
|
Scott White
Company Group Chairman |
|
Thomas J. Spellman
Secretary |
